Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + nivolumab
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Trastuzumab deruxtecan + nivolumab** is a combination of two drugs: trastuzumab deruxtecan (a HER2-targeted antibody-drug conjugate) and nivolumab (an anti–PD-1 monoclonal antibody immune checkpoint inhibitor). Trastuzumab deruxtecan consists of an anti-HER2 antibody, a tetrapeptide-based linker, and a topoisomerase I inhibitor payload, delivering cytotoxic effects selectively to HER2-expressing tumor cells[1]. Nivolumab blocks the PD-1 pathway, promoting T cell-mediated antitumor immune response[1]. The combination is intended to leverage both targeted cytotoxicity and immunotherapy, and has shown promising antitumor activity and manageable safety in HER2-expressing metastatic breast cancer and metastatic urothelial carcinoma[1][5].
- Brand names
- EnhertuOpdivo
- Other names
- fam-trastuzumab deruxtecan-nxki + nivolumab
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab deruxtecan + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + nivolumab.